Podcasts about Fujifilm

Director Mike Pecci joins host David Kruta to dissect the chaos of post-COVID Hollywood, the false promises of AI disruption, and the suffocating gatekeeping of the studio system. Pecci lays bare the existential challenges of trying to create authentic work in an industry gripped by fear, algorithmic control, and vanishing opportunities. In a world where pitching feels like shouting into a void, Pecci finds power in simply continuing to create, and the filmmakers who will survive are the ones who know how to make something out of nothing—and do it with heart. For him, AI is not the enemy. Mediocrity is. Mike Pecci's Instagram | Website | Watch 12 KilometersDavid Kruta's Instagram | WebsiteThis episode is sponsored by Fujifilm, Sandisk and TCP Insurance.

In today's episode the new Sony RX1R III is being released, Fujifilm is releasing an IR version of the X-H2 and GFX100II, Mr Ding's new Noxlux DG 50mm F/1.2 lens and the great Tadeusz Rolke passes away at the age of 96. You can find the show notes here. https://liamphotographypodcast.com/episodes/episode-463-sony-rx1riii-fujifilm-ir-noxlux-dg-50mm-f12

Join this week's episode of Focus Check as we dive into the updated Lab Test results of the LUMIX S1II — and explore how this camera is getting surprisingly close to high-end cinema cameras when it comes to dynamic range. Plus, Sony just dropped a new camera, joining the growing trend of lifestyle-focused cameras alongside brands like FUJIFILM and SIGMA. We're also taking a look at some exciting new lens announcements, including affordable large-format options compatible with cameras like the ALEXA LF and the upcoming FUJIFILM ETERNA. So, as always, hit that play button and enjoy your weekly dose of cine tech news and insights! Sponsor: This episode is sponsored by FUJIFILM. Check it out at  Chapters & Articles Mentioned in This Episode: 15:54 (00:00) – Introduction   (05:25) - Panasonic LUMIX S1II Lab Test, Part 2 – Dynamic Range and Latitude Using ProRes RAW 5.8K with DR Boost “ON” https://www.cined.com/panasonic-lumix-s1ii-lab-test-part-2-dynamic-range-and-latitude-using-prores-raw-5-8k-with-dr-boost-on/   (16:56) - Sony RX1R III Announced – Compact Full-Frame Flagship With 61MP Sensor and AI Autofocus https://www.cined.com/sony-rx1r-iii-announced-compact-full-frame-flagship-with-61mp-sensor-and-ai-autofocus/   (23:53) - LensNode by Node Mill – Vintage Lens Emulation Plugin for DaVinci Resolve Available in Early Access https://www.cined.com/lensnode-by-node-mill-vintage-lens-emulation-plugin-for-davinci-resolve-available-in-early-access/   (30:41) - Simmod Enters the Lens Market – Introducing APSARA LUMIERE & PRESTIGE Lines https://www.cined.com/simmod-enters-the-lens-market-introducing-apsara-lumiere-prestige-lines/   (38:03) - Simmod Lens NATO Ring Introduced – Mount Motors, LiDAR, and More to Cine Lenses https://www.cined.com/simmod-lens-nato-ring-introduced-mount-motors-lidar-and-more-to-cine-lenses/   (40:26) - RØDE Wireless Micro Camera Receiver Announced – Free for Customers https://www.cined.com/rode-wireless-micro-camera-receiver-announced-free-for-customers/   (45:46) - Accsoon CineView M7 Pro and M7 Officially Launched: New Wireless 7” Monitors with Recording Capabilities https://www.cined.com/accsoon-cineview-m7-pro-and-m7-officially-launched-new-wireless-7-monitors-with-recording-capabilities/   (52:33) - NANLITE pico RGBW Pocket Light Announced – CCT Range of 2700K–7500K, Wireless Control https://www.cined.com/nanlite-pico-rgbw-pocket-light-announced-cct-range-of-2700k-7500k-wireless-control/   (55:31) - Extra Shot for Safety, Yes or No? – Various Approaches to Coverage https://www.cined.com/extra-shot-for-safety-yes-or-no-various-approaches-to-coverage/   (01:04:31) - YouTube Set to Crack Down on “AI Slop” with Monetization Policy Update https://www.cined.com/youtube-set-to-crack-down-on-ai-slop-with-monetization-policy-update/    (01:12:39) - Eddie AI “Scripted” Mode Launched – Upload Script & Footage, Get an Instant Rough Cut https://www.cined.com/eddie-ai-scripted-mode-launched-upload-script-footage-get-an-instant-rough-cut/   (01:15:24) - Moonvalley Releases Marey – A “Commercially Safe” AI Video Model Tailored for Professional Filmmakers https://www.cined.com/moonvalley-releases-marey-a-commercially-safe-ai-video-model-tailored-for-professional-filmmakers/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com   

Vadvízi eveztünk egyet Bovec-ben, közösen fotóztunk esküvőt, F1 Movie-t néztünk, majd megtárgyaltuk az utóbbi hetek új termék megjelenéseit.Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/152Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ és a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Bovec evezős videónk:https://youtu.be/1oi0mLusvbE- Fujifilm X-E5:https://www.fujifilm-x.com/global/products/cameras/x-e5/- Manfrotto one állvány:https://www.manfrotto.com/hu-hu/collections/supports/manfrotto-one/Manfrotto Pro Light állvány táska:https://www.manfrotto.com/hu-hu/pro-light-tripod-bag-88-mb-pl-tb-88/Peak Design Pro Tripod:https://www.kickstarter.com/projects/peak-design/pro-tripod-by-peak-design- F1 Movie iPhone modul:https://www.wired.com/story/apple-created-a-custom-iphone-camera-for-f1/- Adobe Project Indigo:https://research.adobe.com/articles/indigo/indigo.html- Smallrig iPhone monitorhttps://www.smallrig.com/Wireless-Video-Monitor-for-Phone-4850.html

Lazy title? Definitely, but in an oddly original way. More odd? The way Mandy says ‘cock the hammer' you'll see……

Merck & Co. has acquired Verona Pharma for $10 billion in a deal designed to expand the pharma giant's portfolio of cardio-pulmonary disease treatments. In a step toward virtual cell benchmarking, the Arc Institute has launched the Virtual Cell Challenge to evaluate the ability of transcriptome AI models to generalize to new cell contexts for therapeutic applications. Fujifilm rebrands life science companies to position itself as a drug development leader. Additionally, AAV-OTOF gene therapy shows promise in restoring hearing loss while a new proteomics tool gleams insight into telomere repair. We wrap up our episode with highlights from BIO 2025, as FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” focused on accelerating drug applications, industry partnerships, and applying AI.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.Listed below are links to the GEN stories referenced in this episode of Touching Base: Merck to Acquire Verona Pharma for $10B, Adding Fast-Growing COPD DrugBy Alex Philippidis, GEN Edge, July 9, 2025 Arc Institute Launces Virtual Cell Challenge to Accelerate AI Model DevelopmentBy Fay Lin, PhD, GEN Edge, June 26, 2025End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle LeaderBy Alex Philippidis, GEN Edge, July 8, 2025AAV-OTOF Gene Therapy Trial Restores Hearing in Both Children and Adults By GEN, July 7, 2025 Proteomics Tool Sheds Light on Cancer Cells' Telomere Repair Tactics By GEN, July 7, 2025 Makary Calls for “New FDA” at BIO; Defends Agency's Spring Job CutsBy Alex Philippidis, GEN Edge, June 18, 2025Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”By Kevin Davies, PhD, and Alex Philippidis, GEN Edge, June 5, 2025 Behind the Breakthroughs PodcastHosted by Jonathan D. Grinstein, PhD Hosted on Acast. See acast.com/privacy for more information.

What feature would you most like to see in the next generation of mirrorless cameras? In this episode, Nino dives into the results of our latest community poll and discusses some of the most interesting suggestions and ideas shared by our listeners. Of course, we also cover this week's gear announcements—including DJI's new Power Stations and the Saramonic TC-Neo timecode box. Tune in to find out what features filmmakers are really hoping for in future camera releases!   Sponsor: This episode is sponsored by FUJIFILM. Check it out at 17:12   Chapters & Articles Mentioned in This Episode: (00:00) – Introduction   (04:26) - Is the FX2 Sony's Best Stills Body Yet? https://www.cined.com/is-the-fx2-sonys-best-stills-body-yet/   (13:12) - Your First Steps in Compositing – New Course “Get Me Started with Adobe After Effects” on MZed https://www.cined.com/your-first-steps-in-compositing-new-course-get-me-started-with-adobe-after-effects-on-mzed/   (18:04) - DJI Power 2000 Introduced – Stackable, Portable Power Station for On-Set and Remote Use https://www.cined.com/dji-power-2000-introduced-stackable-portable-power-station-for-on-set-and-remote-use/   (20:09) - DJI Power 1000 V2 Announced: Faster Charging, Higher Stability for Filmmakers and Adventurers https://www.cined.com/dji-power-1000-v2-announced-faster-charging-higher-stability-for-filmmakers-and-adventurers/   (25:25) - California Raises Film Tax Credits – But Is It Too Late? https://www.cined.com/california-raises-film-tax-credits-but-is-it-too-late/   (32:13) - Poll: What Features are Missing from Today's Mirrorless Cameras? https://www.cined.com/poll-what-features-are-missing-from-todays-mirrorless-cameras/   (01:01:02) - Saramonic TC-NEO Timecode Generator Released – Multi-sync Capable with Unique Charging Case https://www.cined.com/saramonic-tc-neo-timecode-generator-released-multi-sync-capable-with-unique-charging-case/   (01:07:50) - CAMERAMAMAS Roundtable – Inside the Realities of Motherhood as a Cinematographer https://www.cined.com/cameramamas-roundtable-inside-the-realities-of-motherhood-as-a-cinematographer/   (01:12:06) - Sony Implements up to 35% Price Increases on Cameras and Lenses in the US Amid Tariff Pressures https://www.cined.com/sony-implements-up-to-35-price-increases-on-cameras-and-lenses-in-the-us-amid-tariff-pressures/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Neale and Kev swap their stranger wedding adventures, swapping being apt in the case of Kev's revelation! Also on the show, mouse v tablet editing, the money spent on kit we never use (!), great photo galleries and classic British pub suggestions to visit for a special tourist trip to London, how we'd run our photography businesses if we were to start again, advice on setting up an X100VI, Kev's best chess moves in church and the target market for the new X-E5 camera and new 23mm lens Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

Episode 471 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - 20% OFF at ShimodaDesigns.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Don't do this…especially if you have this body. (#) 7Artisans' new 10mm f/3.5. (#) This new lens rounds out the G2 trinity. (#) Apple updates this affordable acquisition. (#) Tamron says it's #1. (#) Want $30,000? Who doesn't. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Industrial expansion has left an indelible mark on our natural world, fundamentally altering landscapes and ecosystems for the sake of material progress and modern convenience. This transformation has created an environmental challenge of unprecedented scale. In today's show, we'll connect the dots between the raw materials that make up our planet and the industrial forces visually altering our contemporary landscape in a chat with a photographer who's documented these profound global changes firsthand for the past 50 years. Applying visual principals rooted in abstract expressionist painting, Edward Burtynsky has explored a wide range of photographic tools in his image making—from large format film to high-res digital cameras mounted to the most sophisticated of drones. Included among our many discussion topics are his distinctive approach to translating a 3-D landscape to the flat plane of a photograph; his various methods for capturing aerials using either a helicopter, fixed wing aircraft, or various types of drones; and the early business epiphany that led him to open a photo lab as an income stream, rather than work as a camera for hire. As Burtynsky shares during our chat, about the connection between nature and industry: “You know, materials are an incredibly key part of modern society. And yet we need to go to sources in nature, where these materials are found. And I'm just reconnecting a reality that we still live in a material world, and our cities are built of molecules that came from somewhere, and I'm taking you to those places that are vast and huge.” Guest: Edward Burtynsky Episode Timeline: 2:58: Burtynsky's early interest in abstract expressionist painting combined with the magic and rituals of composing images with a large format camera 5:28: Planning for aerial views, the shift from using a minerals map in the past to Google Earth today, plus Burtynsky's shooting preferences between a helicopter and a drone and shooting open air. 10:22: Burtynsky's approach to translating a 3-D landscape to the flat plane of a photograph. 17:17: The planning and research behind Burtynsky's work vs the need to pivot in the field. 19:45: Adapting to technology over a 50-year career, and how it's shaped Burtynsky's process—from large format film to high end digital on a drone. 23:16: Episode Break 23:59: Burtynsky talks about permissions to access mines and industrial sites and how this has changed over time. 31:44: A wrong turn on the highway in 1981 and the photos that led Burtynsky to an epiphany about human-altered landscapes.  35:48: Burtynsky talks about forming his photo lab Toronto Image Works as a ballast to provide income in printing for other photographers while pursuing personal fine art photo projects. 43:38: Burtynsky's retrospective exhibit at the ICP in New York, his thoughts about the future of technology, plus recent collaborations with a young artist working in Artificial Intelligence.   Guest Bio:  Edward Burtynsky has spent more than 40 years bearing witness to the impact human industry on our planet. Regarded as one of the world's most accomplished contemporary photographers, Burtynsky's work is included in the collections of more than 80 museums worldwide and featured in major exhibitions around the globe. Born in St. Catharines, Ontario in 1955, Burtynsky's early exposure to a nearby General Motors plant and ships navigating the Welland Canal in his hometown captured his imagination, helping to formulate his ideas about the scale of human creation he would later capture in photographs. These images explore the collective impact we as a species have on the surface of this planet. A select list of Burtynsky's many distinctions include the inaugural TED Prize, the title of Officer of the Order of Canada, the International Center of Photography's Infinity Award for Art, a Royal Photographic Society Honorary Fellowship, and the World Photography Organization's Outstanding Contribution to Photography Award. Burtynsky currently holds nine honorary doctorate degrees, and in addition to his work in photography, he was a key production figure in the award-winning documentary film trilogy Manufactured Landscapes, Watermark, and ANTHROPOCENE: The Human Epoch. All three films continue to play in festivals around the world. Stay Connected: Website Instagram Facebook YouTube Linktree    - Host: Derek Fahsbender  Senior Creative Producer: Jill Waterman Senior Technical Producer: Mike Weinstein Executive Producer: Richard Stevens

Cybersecurity researchers have uncovered a serious flaw affecting nearly 700 Brother printer models that allows attackers to extract serial numbers and generate admin passwords without any authentication. Host Mikah Sargent walks through the step-by-step process of securing your Mac-connected printer using built-in macOS tools to access your printer's web interface and change those dangerous default passwords. • Major Printer Security Vulnerability Discovered - Rapid7 cybersecurity company found flaws affecting Brother, Toshiba, and Fujifilm printers, with 689 Brother models impacted by the most serious vulnerability • How the Attack Works - Bad actors can access printers without authentication, extract serial numbers, and use them to generate default admin passwords since manufacturers use predictable password generation methods • Viewing Printer Details and Options - How to check printer queue, sharing settings, driver information, and supply levels through the macOS interface for connected Brother printers • Opening Your Printer's Web Interface - Step-by-step guide to accessing the "Show Printer Web Page" option to reach your printer's built-in web server for advanced configuration • Checking and Updating Firmware - Importance of keeping printer firmware current, though updates don't completely solve the manufacturing-level vulnerability that requires Brother to address • Changing Default Admin Passwords - Critical security step of accessing the administrator login settings through the printer's web interface to replace factory default credentials Host: Mikah Sargent Download or subscribe to Hands-On Apple at https://twit.tv/shows/hands-on-apple Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

To celebrate the summer, DxO is offering a great deal for the PetaPixel Podcast listeners. You can get 25% off any DxO software, including Nik Collection 8, by using the code JULY25 at checkout. This is a limited-time offer for new customers, valid until July 6th, so, if you want to unlock some serious creative potential, head over to dxo.com and check out Nik Collection 8. Use code JULY25 to save 25%!In what is quickly becoming a bi-annual tradition, the PetaPixel Podcast team welcomes Camera Labs' Gordon Laing back onto the pod to play proctor! It's time for the midterms: how is every camera maker doing so far in 2025? Well, that is, if they decided to show up and take the test. Support Chris and Jordan directly with a PetaPixel Membership!Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.In This Episode00:00 - Intro11:58 - Tamron has a new 16-30mm f/2.8 G214:11- Tamron says it's the #1 third-party lens maker by total sales15:38 - You can finally download that big Z8 firmware update16:11- But that Z8 update borked Tamron lenses18:16 - Sadly no, Fujifilm isn't bringing back beloved old films19:51 - About that Leica film... 21:55 - The specific things Mint updated in the production Rollei35AF24:42 - Midterm Review: Grading Every Camera Maker's 2025 Performance w/ Gordon Laing

As fears mount over AI's impact on creative labor, cinematographer and technologist Jim Geduldick joins host David Kruta to dissect the frenzy surrounding artificial intelligence and its encroachment into the film industry. As AI-generated imagery floods social media and marketing departments chase cost-cutting automation, Geduldick challenges the doom-and-gloom narrative with a nuanced, insider perspective—arguing that while jobs may shift, human storytelling will remain irreplaceable. However, decades of tech disruption, from DVX100s to LED volumes, won't change the fact that great filmmaking has always been—and still is—about the people behind the lens.Jim Geduldick's InstagramDavid Kruta's Instagram | WebsiteThis episode is sponsored by Fujifilm, Sandisk and TCP Insurance.

Cybersecurity researchers have uncovered a serious flaw affecting nearly 700 Brother printer models that allows attackers to extract serial numbers and generate admin passwords without any authentication. Host Mikah Sargent walks through the step-by-step process of securing your Mac-connected printer using built-in macOS tools to access your printer's web interface and change those dangerous default passwords. • Major Printer Security Vulnerability Discovered - Rapid7 cybersecurity company found flaws affecting Brother, Toshiba, and Fujifilm printers, with 689 Brother models impacted by the most serious vulnerability • How the Attack Works - Bad actors can access printers without authentication, extract serial numbers, and use them to generate default admin passwords since manufacturers use predictable password generation methods • Viewing Printer Details and Options - How to check printer queue, sharing settings, driver information, and supply levels through the macOS interface for connected Brother printers • Opening Your Printer's Web Interface - Step-by-step guide to accessing the "Show Printer Web Page" option to reach your printer's built-in web server for advanced configuration • Checking and Updating Firmware - Importance of keeping printer firmware current, though updates don't completely solve the manufacturing-level vulnerability that requires Brother to address • Changing Default Admin Passwords - Critical security step of accessing the administrator login settings through the printer's web interface to replace factory default credentials Host: Mikah Sargent Download or subscribe to Hands-On Apple at https://twit.tv/shows/hands-on-apple Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

Send us a textIn this episode of Street Life, John and Mark had the incredible opportunity to speak with Tatsuo Suzuki, a celebrated street photographer based in Tokyo. Tatsuo is known for his bold, high-contrast imagery and his unique approach to capturing raw human emotion.We delved into his journey into photography, which began later in life after his time in a rock band and a corporate job. He shared how he found self-expression through photography, particularly street photography, and how his experiences shaped his artistic vision.Tatsuo opened up about his early influences, including iconic photographers like Daido Moriyama and Robert Frank, and discussed the importance of intimacy in his work, especially when photographing marginalised communities like the homeless. We explored the ethical considerations of street photography and how Tatsuya navigates the fine line between capturing candid moments and respecting his subjects.A significant portion of our conversation focused on Tatsuo's recent work, including his book "The Sound of Waves," which he created as a tribute to a late friend and fellow photographer. He explained the symbolism of water and life in his series, emphasising the emotional depth behind his images.We also touched on the Fujifilm controversy that Tatsuo faced, where he clarified misconceptions about his role in a promotional video and expressed his thoughts on the impact it had on his career.As we wrapped up, Tatsuo shared his thoughts on the legacy he hopes to leave behind and the significance of community in photography, particularly through his collective, Void Tokyo. We hope you enjoy listening to Tatsuo's story as much as we enjoyed sharing it!WEBSITE | INSTAGRAMFollow us on Instagram and leave us a review!

Sometimes, new films demand such unique technical requirements that they end up pushing the boundaries of camera technology. The upcoming F1 movie is a perfect example—two tech giants, Sony and Apple, developed custom cameras specifically for capturing the extreme conditions of Formula 1 racing, with cars reaching speeds of up to 375 km/h. This week, we take a closer look at what it takes to shoot high-speed action like this, and how innovation behind the scenes shapes what we see on screen. We also touch on several other fresh updates from the world of cameras, lenses, and production tools. Tune in for an insightful conversation!   Sponsor: This episode is sponsored by FUJIFILM. Check it out at (27:11)   Chapters & Articles Mentioned in This Episode: (00:00) – Introduction   (04:01) - How F1: The Movie Used a Custom Sony Compact Body, Apple's Custom iPhone Camera and VENICE 2 to Capture Speed  https://www.cined.com/how-f1-the-movie-used-a-custom-sony-compact-body-and-apples-custom-iphone-camera-to-capture-speed/   (17:11) - Filmmaking for the Vision Pro Era: Apple and Blackmagic's Immersive Video Workflow https://www.cined.com/filmmaking-for-the-vision-pro-era-apple-and-blackmagics-immersive-video-workflow/   (23:43) - Saramonic Air – Compact, Dual-Channel, Wireless Mic Introduced for Quick Shoots https://www.cined.com/saramonic-air-compact-dual-channel-wireless-mic-introduced-for-quick-shoots/    (28:05) - Godox KNOWLED M300R RGBWW LED Light Announced https://www.cined.com/godox-knowled-m300r-rgbww-led-light-announced/   (35:44) - The Director's Guide to Everything by Jay Holben- a 600-Page Book for Directors at Any Level https://www.cined.com/the-directors-guide-to-everything-by-jay-holben-a-600-page-book-for-directors-at-any-level/   (39:18) - Adobe Firefly Sound Generator Debuts – Custom SFX Guided by Your Voice https://www.cined.com/adobe-firefly-sound-generator-debuts-custom-sfx-guided-by-your-voice/   (43:41) - Tamron 16-30mm f/2.8 Di III VXD G2 Wide-Angle Zoom Full-Frame Lens Announced https://www.cined.com/tamron-16-30mm-f-2-8-di-iii-vxd-g2-wide-angle-zoom-full-frame-lens-announced/   (47:51) - Sony Addresses BURANO Color Reproduction Issues with Free IR Cut Filter Replacement https://www.cined.com/sony-addresses-burano-color-reproduction-issues-with-free-ir-cut-filter-replacement/   (51:34) - Sony's ‘Camera Verify' Feature Launched to Strengthen Image Authenticity for Newsrooms https://www.cined.com/sonys-camera-verify-feature-launched-to-strengthen-image-authenticity-for-newsrooms/   (53:37) - Mastering Feedback – A Filmmaker's Guide to Creative Collaboration https://www.cined.com/mastering-feedback-a-filmmakers-guide-to-creative-collaboration/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Cybersecurity researchers have uncovered a serious flaw affecting nearly 700 Brother printer models that allows attackers to extract serial numbers and generate admin passwords without any authentication. Host Mikah Sargent walks through the step-by-step process of securing your Mac-connected printer using built-in macOS tools to access your printer's web interface and change those dangerous default passwords. • Major Printer Security Vulnerability Discovered - Rapid7 cybersecurity company found flaws affecting Brother, Toshiba, and Fujifilm printers, with 689 Brother models impacted by the most serious vulnerability • How the Attack Works - Bad actors can access printers without authentication, extract serial numbers, and use them to generate default admin passwords since manufacturers use predictable password generation methods • Viewing Printer Details and Options - How to check printer queue, sharing settings, driver information, and supply levels through the macOS interface for connected Brother printers • Opening Your Printer's Web Interface - Step-by-step guide to accessing the "Show Printer Web Page" option to reach your printer's built-in web server for advanced configuration • Checking and Updating Firmware - Importance of keeping printer firmware current, though updates don't completely solve the manufacturing-level vulnerability that requires Brother to address • Changing Default Admin Passwords - Critical security step of accessing the administrator login settings through the printer's web interface to replace factory default credentials Host: Mikah Sargent Download or subscribe to Hands-On Apple at https://twit.tv/shows/hands-on-apple Want access to the ad-free video and exclusive features? Become a member of Club TWiT today! https://twit.tv/clubtwit Club TWiT members can discuss this episode and leave feedback in the Club TWiT Discord.

In this powerful conversation, Bill Drysdale, former General Manager of Fujifilm's $500M digital camera division and current Vistage Chair, opens up about the reality of CEO isolation and the "heavy backpack" of leadership responsibilities. Bill shares how he felt isolated despite being surrounded by colleagues and discusses the three major challenges that create the deepest isolation for CEOs - people decisions, financial strain, and legal/ethical issues. Drawing from his experience facilitating peer advisory groups, Bill reveals how vulnerability and peer connection can transform both decision-making and business performance, offering practical insights for leaders ready to break through isolation.

North Korean IT Worker Fraud Scheme:The U.S. Department of Justice uncovered a covert North Korean operation involving IT workers fraudulently securing remote jobs at over 100 American tech companies using stolen or fake identities. These workers operated within U.S.-based "laptop farms" and created shell companies to obscure over $5 million in illicit earnings. Funds were funneled to the North Korean government, supporting weapons development. The scheme also involved data theft, including sensitive source code from a U.S. defense contractor.Android 16 Anti-Surveillance Feature:Android 16 introduces a “network notification” security upgrade that alerts users when their device connects to suspicious or unencrypted cell networks. It specifically guards against fake cell towers, such as stingray devices, by warning users about network requests for identifiers or lack of encryption, enhancing protection from mobile surveillance and forced downgrades to insecure protocols.Critical Printer Vulnerabilities:Rapid7 researchers identified eight major vulnerabilities affecting printers from Brother, Ricoh, Toshiba, Konica Minolta, and Fujifilm. The most critical flaw (CVE-2024-51978) lets remote attackers bypass admin authentication by exploiting a companion vulnerability (CVE-2024-51977) that reveals the printer's serial number—used to generate default admin credentials. This enables unauthorized reconfiguration and access to stored sensitive documents.Microsoft Authenticator Password Phase-Out:Microsoft will remove password autofill and access features from its Authenticator app starting July 2025. The move supports a transition to passwordless sign-ins using biometrics (e.g., facial recognition, fingerprints) and passkeys, aligning with industry shifts toward stronger, phishing-resistant authentication methods.NIH Open-Access Research Mandate:A new U.S. NIH policy mandates that all taxpayer-funded research be freely accessible upon publication. This accelerates an open-access directive initiated under Biden and implemented during the Trump administration. The policy enhances public access to scientific discoveries and may enable AI tools to help interpret complex studies for broader audiences.Pro-Scottish Independence Account Shutdowns:On June 12, multiple X (formerly Twitter) accounts advocating for Scottish independence vanished in sync with an Israeli cyber strike on Iran. The timing and scope of internet outages in Iran imply that the accounts were likely Iranian-run disinformation tools designed to destabilize the UK under the guise of grassroots political advocacy.Facebook Camera Roll Upload Concerns:Facebook is asking users to opt in to uploading unshared photos from their camera roll to Meta's servers to enable AI-generated content (e.g., collages). While Meta states that content remains private and isn't used for advertising, users must accept AI Terms that permit facial recognition, retention of loosely defined personal data, and potential human review—raising serious privacy concerns over intimate, unshared images.Meta's AI Superlab Push:Meta has launched “Meta Superintelligence Labs” and is heavily investing in top AI talent, reportedly offering compensation packages in the $10 million range. This underscores Meta's ambition to lead in high-end AI development, marking its entry into the elite tier of the global “AI arms race” beyond consumer-facing chatbots.

Mit dieser Episode von Momente Deiner Geschichte gibt es endlich mal wieder ein "On Location", dieses Mal zu einer Streetphotography-Session in Öhringen!Ich wünsche Dir ganz viel Spaß beim Zuhören =)-----Wenn Dir meine Inhalte gefallen, denke bitte daran diesen Podcast positiv auf Deiner jeweiligen Plattform zu bewerten oder vielleicht sogar eine Rezension zu schreiben! Damit würdest Du mir, aber vor allem der ganzen Community, wirklich sehr helfen! DANKEMeine Website: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.benediktbrecht.de⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/momentedeinergeschichte/⁠⁠⁠⁠⁠⁠⁠⁠Facebook:⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/momentedeinergeschichte⁠⁠⁠⁠⁠⁠⁠⁠MdG-Community auf Facebook:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.facebook.com/groups/313021897452285⁠⁠⁠⁠⁠⁠⁠⁠Du möchtest mich mit einem kleinen, einmaligen oder regelmäßigen Beitrag unterstützen und mir so einen ganz besonderen Dank zukommen lassen? Ich meine, denke an meine KaffeSucht...⁠⁠⁠⁠⁠⁠⁠⁠https://buymeacoffee.com/benvonmdg⁠⁠⁠⁠⁠⁠⁠⁠Heute schon getaggt? =)Benutzt Du schon den #momentedeinergeschichte ? Damit können wir uns gegenseitig finden und voneinander lernen! Geht schnell, kostet nix und ist ziemlich stylisch, finde ich^^

➡️➡️ ENLACE PLAUD: https://bit.ly/plaud_ai_ruben

Benedekkel beszélgettünk elérhetetlen árú álom órákról, Ricoh GRIV-ről, a tökéletes mindennapi kameráról, és az új Fujifilm X-Half-ról. Az adás végén Benedek mesélt a washingtoni projektjéről és annak lezárásáról és a lezárással kapcsolatos dilemmákról.Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/151⁠Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ és a ⁠⁠⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- Garmin Fenix 8:https://garmin.hu/fenix8- Garmin Instinct 3:https://garmin.hu/okosorak/instinct/instinct-3-50mm-amoled-tropic-szurke-szijjal-ed- Omega Seamaster Aqua Terra:https://www.omegawatches.com/watches/seamaster/aqua-terra-150m/catalog- Patek Philippe Nautilus:https://www.patek.com/en/collection/nautilus- Grand Seiko:https://www.grand-seiko.com/uk-en/Rolex Datejust:https://www.rolex.com/watches/datejust- IWC:https://www.iwc.com/en/home.html- Hamilton Khaki Day Date Auto:https://www.hamiltonwatch.com/en-int/h64615135-khaki-aviation-pilot-day-date-auto.html- Hamilton Khaki Murph:https://www.hamiltonwatch.com/en-int/hamilton-khaki-field-murph- Omega Seamaster James Bond:https://www.omegawatches.com/planet-omega/cinema/james-bond- Sinn 556i:https://www.sinn.de/en/watches/556-i.html- Ricoh GRIV bejelentés:https://ricohgr.eu/blogs/news/22-05-2025-development-anouncement-of-ricoh-gr-iv?srsltid=AfmBOooh3jXyDBEqY9Wspgy9xplhfqjkuI4ZciINuZDKEctB0I3rHzah- Fuji X-Half "film" visszatekerés:https://youtu.be/Dk77g7scnn0?si=ddJNfTmTE0YRuoov&t=1079- Benedek sorozata - We painted the sky to remember:https://benedekvarga.com/projects-Kz0uW/we-painted-the-sky-to-remember- Godox iT30Pro:https://www.godox.com/product-e/iT30Pro.html

Join this week's discussion with Johnnie and Nino! While there haven't been any major camera announcements, we're working on something exciting—our very own CineD Camera Bag. We're sharing the journey behind the project and exploring what's possible. Plus, there are a few new camera updates, a fresh lens release, and some new tripods worth talking about. As always, tune in and stick around until the end!   Sponsor: This episode is sponsored by FUJIFILM. Check it out at 20:25 Chapters & Articles Mentioned in This Episode: (00:00) – Introduction   (04:37) - Poll: Camera to Cloud Workflow – How Much Has This Technology Really Caught On? https://www.cined.com/poll-camera-to-cloud-workflow-how-much-has-this-technology-really-caught-on/   (11:10) - Hohem iSteady M7 AI Tracking Smartphone Gimbal Stabilizer – First look https://www.cined.com/hohem-isteady-m7-ai-tracking-smartphone-gimbal-stabilizer-first-look/   (16:02) - A CineD Bag – Call for Action for Manufacturers https://www.cined.com/a-cined-bag-call-for-action-for-manufacturers/   (21:17) - Magic Lantern is Back and Supports New Cameras Such as EOS 200D, 6D Mark II, and 7D Mark II https://www.cined.com/magic-lantern-is-back-and-supports-new-cameras-such-as-eos-200d-6d-mark-ii-and-7d-mark-ii/   (28:22) - Panasonic Firmware updates for LUMIX S1RII, S1II, and S1IIE Cameras Announced https://www.cined.com/panasonic-firmware-updates-for-lumix-s1rii-s1ii-and-s1iie-cameras-announced/ (31:54) - Blackmagic Camera 9.6 Update Enhances Micro Studio Camera 4K G2 https://www.cined.com/blackmagic-camera-9-6-update-enhances-micro-studio-camera-4k-g2/   (36:32) - iPadOS 26 Will Enable Background Renders for Final Cut Pro & DaVinci Resolve https://www.cined.com/ipados-26-will-enable-background-renders-for-final-cut-pro-davinci-resolve/   (44:37) - Inside the First Feature-Length Immersive Film for Apple Vision Pro: Bono – Stories of Surrender https://www.cined.com/inside-the-first-feature-length-immersive-film-for-apple-vision-pro-bono-stories-of-surrender/   (47:16) - Peak Design Pro Tripod Launched https://www.cined.com/peak-design-pro-tripod-launched/   (51:59) - Laowa 8-15mm Fisheye Full-Frame Lenses Introduced – Circular and Rectangular Fisheye in One Lens https://www.cined.com/laowa-8-15mm-fisheye-full-frame-lenses-introduced-circular-and-rectangular-fisheye-in-one-lens/   (53:43) - Eddie AI Update Announced – Support for Multiple Languages, B-roll and A-roll Logging https://www.cined.com/eddie-ai-update-announced-support-for-multiple-languages-b-roll-and-a-roll-logging/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com   

¿El ojo del fotógrafo o la cámara? Esa es la pregunta que intentamos responder en este experimento fotográfico único. Le entregamos una cámara promocional de Kokoriko–CocaCola con un rollo nuevo de Fujifilm 200 ASA a alguien que jamás había disparado en película y la mandamos por 15 días a recorrer México. ¿Qué salió de esos negativos? ¿El arte está en la mirada del fotógrafo o en las prestaciones del equipo?En este video descubrirás los resultados sorprendentes de esa aventura visual. Revelamos los negativos, analizamos las tomas y reflexionamos sobre el verdadero valor de la fotografía en la era analógica. Te garantizo que lo que verás va más allá de lo técnico y entra de lleno en la magia del momento capturado.

Episode 470 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - 20% OFF Nanlite PavoTube II XR and kits at NanliteUS.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Adobe announces some potentially useful new features. (#) Sigma's new 17-40mm f/1.8 DC Art. (#) Profoto's new B20 and B30 monolights. (#) Peak Design's latest tripod Kickstarter. (#) Godox's V480C TTL flash. (#) Leica's first filmstock to celebrate 100 years of this. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

We've reached 300 episodes! What's changed since the first one, from a time we didn't even see a pandemic coming? Well, for a start, the DSLR has quietly taken its place in the museum, while Kodak, CineStill, and Fujifilm ramped up film production, as demand for analogue exploded again; turns out grain never really went out of fashion. Medium format isn't chained to a tripod anymore either. With Fujifilm's GFX line, photographers are now shooting huge resolutions on something that fits in a shoulder bag. Oh, and then there's AI. In 2019, you might rightly have shouted, “A WOT?” Now it's the invisible hand behind how clients and an audience find you. With more people using AI to search instead of scrolling Google pages, your website, your words, your presence, they all need to speak a language that machines can read, as well as humans. Also on the show, Kev's Driving School has started its engine, AI writes us some poetry, things to change on your website to allow AI to seek you, what to say when a client asks to see the raw photos from a shoot, buying the latest GFX, film photography borders on your website, and SCRL. Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

Dr. John Sweetenham and Dr. Erika Hamilton highlight key abstracts that were presented at ASCO25, including advances in breast and pancreatic cancers as well as remarkable data from the use of structured exercise programs in cancer care. Transcript Dr. Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. Today, we'll be discussing some of the key advances and novel approaches in cancer care that were presented at the 2025 ASCO Annual Meeting. I'm delighted to be joined again by the chair of the Meeting's Scientific Program, Dr. Erika Hamilton. She is a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee.  Our full disclosures are available in the transcript of this episode. Dr. Hamilton, congratulations on a fantastic meeting. From the practice-changing science to the world-renowned speakers at this year's Meeting, ASCO25 really reflected the amazing progress we're seeing in oncology today and the enormous opportunities that lie ahead of us. And thanks for coming back on to the podcast today to discuss some of these advances. Dr. Hamilton: Thanks, Dr. Sweetenham. I'm happy to join you today. It really was an impactful ASCO Annual Meeting. I probably am biased, but some great research was presented this year, and I heard lots of great conversations happening while we were there. Dr. Sweetenham: Yeah, absolutely. There was a lot of buzz, as well as a lot of media buzz around the meeting this year, and I think that's probably a good place to start. So I'd like to dive into abstract number LBA3510. This was the CHALLENGE trial, which created a lot of buzz at the meeting and subsequently in the media. This is the study that was led by the NCI Canada Clinical Trials Group, which was the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer, which demonstrated that a post-treatment structured exercise program is both feasible and effective in improving disease-free survival in this patient group. The study was performed over a long period of time and in many respects is quite remarkable. So, I wonder if you could give us your thoughts about this study and whether you think that this means that our futures are going to be full of structured exercise programs for those patients who may benefit. Dr. Hamilton: It's a fantastic question. I think that this abstract did create a lot of buzz. We were very excited when we read it. It was highlighted in one of the Clinical Science Symposium sessions. But briefly, this was a phase 3 randomized trial. It was conducted at 55 centers, so really a broad experience, and patients that had resected colon cancer who completed adjuvant therapy were allowed to participate. There were essentially 2 groups: a structured exercise program, called ‘the exercise group,' or health education materials alone, so that was called just ‘the health education group.' And this was a 3-year intervention, so very high quality. The primary end point, as you mentioned, was disease-free survival. This actually accrued from 2009 to 2024, so quite a lift, and almost 900 patients underwent randomization to the exercise group or the health education group. And at almost 8 years of follow-up, we saw that the disease-free survival was significantly longer in the exercise group than the health education group. This was essentially 80.3% of patients were disease-free in exercise and 73.9% in the health education group. So a difference of over 6 percentage points, which, you know, at least in the breast cancer world, we make decisions about whether to do chemotherapy or not based on these kind of data. We also looked at overall survival in the exercise group and health education group, and the 8-year overall survival was 90.3% in the exercise group and 83.2% in the health education group. So this was a difference of 7.1%. Still statistically significant. I think this was really a fantastic effort over more than a decade at over 50 institutions with almost 900 patients, really done in a very systematic, high-intervention way that showed a fantastic result. Absolutely generalizable for patients with colon cancer. We have hints in other cancers that this is beneficial, and frankly, for our patients for other comorbidities, such as cardiovascular, etc., I really think that this is an abstract that deserved the press that it received. Dr. Sweetenham: Yeah, absolutely, and it is going to be very interesting, I think, over the next 2 or 3 years to see how much impact this particular study might have on programs across the country and across the world actually, in terms of what they do in this kind of adjuvant setting for structured exercise. Dr. Hamilton: Absolutely.  So let's move on to Abstract 3006. This was an NCI-led effort comparing genomic testing using ctDNA and tissue from patients with less common cancers who were enrolled in but not eligible for a treatment arm of the NCI-MATCH trial. Tell us about your takeaways from this study. Dr. Sweetenham: Yeah, so I thought this was a really interesting study based, as you said, on NCI-MATCH. And many of the listeners will probably remember that the original NCI-MATCH study screened almost 6,000 patients to assess eligibility for those who had an actionable mutation. And it turned out that about 60% of the patients who went on to the study had less common tumors, which were defined as anything other than colon, rectum, breast, non–small cell lung cancer, or prostate cancer. And most of those patients lacked an eligible mutation of interest and so didn't get onto a trial therapy. But with a great deal of foresight, the study group had actually collected plasma samples from these patients so that they would have the opportunity to look at circulating tumor DNA profiles with the potential being that this might be another way for testing for clinically relevant mutations in some of these less common cancer types. So initially, they tested more than 2,000 patients, and to make a somewhat complicated story short, there was a subset of five histologies with a larger representation in terms of sample size. And these were cholangiocarcinoma, small cell lung cancer, esophageal cancer, pancreatic, and salivary gland cancer. And in those particular tumors, when they compared the ctDNA sequencing with the original tumor, there was a concordance there of around 84%, 85%. And in the presentation, the investigators go on to list the specific mutated genes that were identified in each of those tumors. But I think that the other compelling part of this study from my perspective was not just that concordance, which suggests that there's an opportunity there for the use of ctDNA instead of tumor biopsies in some of these situations, but what was also interesting was the fact that there were several clinically relevant mutations which were detected only in the circulating tumor DNA. And a couple of examples of those included IDH1 for cholangiocarcinoma, BRAF and p53 in several histologies, and microsatellite instability was most prevalent in small cell lung cancer in the ctDNA. So I think that what this demonstrates is that liquid biopsy is certainly a viable screening option for patients who are being assessed for matching for targeted therapies in clinical trials. The fact that some of these mutations were only seen in the ctDNA and not in the primary tumor specimen certainly suggests that there's some tumor heterogeneity. But I think that for me, the most compelling part of this study was the fact that many of these mutations were only picked up in the plasma. And so, as the authors concluded, they believe that a comprehensive gene profiling with circulating tumor DNA probably should be included as a primary screening modality in future trials of targeted therapy of this type. Dr. Hamilton: Yeah, I think that that's really interesting and mirrors a lot of data that we've been seeing. At least in breast cancer, you know, we still do a biopsy up front to make sure that our markers, we're still treating the right disease that we think we are. But it really speaks to the utility of using ctDNA for serial monitoring and the emergence of mutations. Dr. Sweetenham: Absolutely. And you mentioned breast cancer, and so I'd like to dwell on that for a moment here because obviously, there was a huge amount of exciting breast cancer data presented at the meeting this year. And in particular, I'd like to ask you about LBA1008, the DESTINY-Breast09 clinical trial, which I think has the potential to establish a new first-line standard of care for metastatic HER2+ breast cancer. And that's an area where we haven't seen a whole lot of innovation for around a decade now. So can you give us some of the highlights of this trial and what your thinking is, having seen the results? Dr. Hamilton: Yeah, absolutely. So this was a trial in the first-line metastatic HER2 setting. So this was looking at trastuzumab deruxtecan. We certainly have had no shortage of reports around this drug, initially approved for later lines. DESTINY-Breast03 brought it into our second-line setting for HER2+ disease and we're now looking at DESTINY-Breast09 in first-line. So this actually was a 3-arm trial where patients were randomized 1:1:1 against standard taxane/trastuzumab/pertuzumab in one arm; trastuzumab deruxtecan with pertuzumab in another arm; and then a third arm, trastuzumab deruxtecan alone. And what we did not see reported was that trastuzumab deruxtecan-alone arm. But we did have reports from the trastuzumab deruxtecan plus pertuzumab versus the chemo/trastuzumab/pertuzumab. And what we saw was a statistically significant improvement in median progression-free survival, 26.9 months up to 40.7, so an improvement of 13.8 months, over a year in PFS. Not to mention that we're now in the 40-month range for PFS in first-line disease. Really, across all subgroups, we really weren't able to pick out a subset of patients that did not benefit. We did see about a 12% ILD rate with trastuzumab deruxtecan. That really is on par with what we've seen in other studies, around 10%-15%. I think that this is going to become a new standard of care in the first-line. I think it did leave some unanswered questions. We saw some data from the PATINA trial this past San Antonio Breast, looking at the addition of endocrine therapy with or without a CDK4/6 inhibitor, palbociclib, for those patients that also have ER+ disease, after taxane has dropped out in the first-line setting. So how we're going to kind of merge all this together is, I suspect that there are going to be patients that we or they just don't have the appetite to continue 3 to 4 years of trastuzumab deruxtecan. And so we're probably going to be looking at a maintenance-type strategy for them, maybe integrating the PATINA data there. But how we really put this into practice in the first-line setting and if or when we think about de-escalating down from trastuzumab deruxtecan to antibody therapy are some lingering questions. Dr. Sweetenham: Okay, so certainly is going to influence practice, but watch this space for a little bit longer, it sounds as though that's what you're saying. Dr. Hamilton: Absolutely.  So let's move on to GI cancer. Abstract 4006 reported preliminary results from the randomized phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel versus the chemo gemcitabine/nab-paclitaxel alone in patients with previously untreated metastatic pancreatic cancer. Can you tell us more about this study? Dr. Sweetenham: Yeah, absolutely. As you mentioned, elraglusib is actually a first-in-class inhibitor of GSK3-beta, which has multiple potential actions in pancreatic cancer. But the drug itself may be involved in mediating drug resistance as well as in some tumor immune response modulation. Some of that's not clearly understood, I believe, right now. But certainly, preclinical data suggests that the drug may be effective in preclinical models and may also be effective in combination with chemotherapy and potentially with immune-modulating agents as well. So this particular study, as you said, was an open-label, randomized phase 2 study in which patients with pancreatic cancer were randomized 2:1 in favor of the elraglusib plus GMP—gemcitabine and nab-paclitaxel—versus the chemotherapy alone. And upon completion of the study, which is not right now, median overall survival was the primary end point, but there are a number of other end points which I'll talk about in just a moment. But the sample size was planned to be around 207 patients. The primary analysis included 155 patients in the combination arm versus 78 patients in the gemcitabine/nab-paclitaxel arm. Overall, the 1-year overall survival rate was 44.1% for the patients in the elraglusib-containing arm versus 23.0% in the patients receiving gemcitabine/nab-paclitaxel only. When they look at the median overall survival, it was 9.3 months for the experimental arm versus 7.2 months for chemotherapy alone. So put another way, there's around a 37% reduction in the risk of death with the use of this combination arm. The treatment was overall well-tolerated. There were some issues with grade 1 to 2 transient visual impairment in a large proportion of the patients. The most common treatment-related adverse effects with the elraglusib/GMP combination was transient visual impairment, which affected around 60% of the patients. Most of the more serious treatment-related adverse events included neutropenia, anemia, and fatigue in 50%, 25%, and 16% of the patients, respectively. So the early results from this study show a significant benefit for 1-year overall survival and for median overall survival with, as I mentioned above, a significant reduction in the risk of death. The authors went on to mention that the median overall survival for the control arm in this study is somewhat lower than in other comparable trials, but they think that this may be related to a more advanced disease burden in this particular study. Of interest to me was that right now: there is no apparent difference in progression-free survival between the 2 arms of this study. The authors described this as potentially indicating that this may be related in some way to immune modulation and immune effects on the tumor, which, if I'm completely honest, I don't totally understand. And so, the improvement in overall survival, as far as I can see at the moment, is not matched by an improvement in progression-free survival. So I think we probably need to wait for more time to elapse to see what happens with the study. And so, I think it certainly is an interesting study, and the results are intriguing, but I think it's probably a little early for it to actually shift the treatment paradigm in this disease. Dr. Hamilton: Fantastic. I think we've been waiting for advances in pancreatic cancer for a long time, but this, not unlike others, we learn more and then learn more we don't realize, so. Dr. Sweetenham: Right. Let's shift gears at this point and talk about a couple of other abstracts in kind of a very different space. Let's start out with symptom management for older adults with cancer. We know that undertreated symptoms are common among the older patient population, and Abstract 11002 reported on a randomized trial that demonstrated the effects of remote monitoring for older patients with cancer in terms of kind of symptoms and so on. Can you tell us a little bit about this study and whether you think this approach will potentially improve care for older patients? Dr. Hamilton: Yeah, I really liked this abstract. It was conducted through the Veterans Affairs, and it was based in California, which I'm telling you that because it's going to have a little bit of an implication later on. But essentially, adults that were 75 years or older who were Medicare Advantage beneficiaries were eligible to participate. Forty-three clinics in Southern California and Arizona, and patients were randomized either into a control group of usual clinic care alone, or an intervention group, which was usual care plus a lay health worker-led proactive telephone-based weekly symptom assessment, and this was for 12 months using the validated Edmonton Symptom Assessment System. So, there was a planned enrollment of at least 200 patients in each group. They successfully met that. And this lay health worker reviewed assessments with a physician assistant, who conducted follow-up for symptoms that changed by 2 points from a prior assessment or were rated 4 or greater. So almost a triage system to figure out who needed to be reached out to and to kind of work on symptoms. What I thought was fantastic about this was it was very representative of where it enrolled. There were actually about 50% of patients enrolled here that were Hispanic or Latinos. So some of our underserved populations and really across a wide variety of tumor types. They found that the intervention group had 53% lower odds of emergency room use, 68% lower odds of hospital use than the control group. And when they translated this to actual total cost of care, this was a savings of about $12,000 U.S. per participant and 75% lower odds of a death in an acute care facility. So I thought this was really interesting for a variety of reasons. One, certainly health care utilization and cost, but even more so, I think any of our patients would want to prevent hospitalizations and ER visits. Normally, that's not a fantastic experience having to feel poorly enough that you're in the emergency room or the hospital. And really showing in kind of concrete metrics that we were able to decrease this with this intervention. In terms of sustainability and scalability, I think the question is really the workforce to do this. Obviously, you know, this is going to take dedicated employees to have the ability to reach out to these patients, etc., but I think in value-based care, there's definitely a possibility of having reimbursement and having the funds to institute a program like this. So, definitely thought-provoking, and I hope it leads to more interventions. Dr. Sweetenham: Yeah, we've seen, over several years now, many of these studies which have looked at remote symptom monitoring and so on in this patient population, and many of them do show benefits for that in kinds of end points, not the least in this study being hospitalization and emergency room avoidance. But I think the scalability and personnel issue is a huge one, and I do wonder at some level whether we may see some AI-based platforms coming along that could actually help with this and provide interactions with these patients outside of actual real people, or at least in combination with real people. Dr. Hamilton: Yeah, that's a fantastic point.  So let's talk a little bit about clinical trials. So eligibility assessment for oncology clinical trials, or prescreening, really relies on manual review of unstructured clinical notes. It's time-consuming, it's prone to errors, and Abstract 1508 reported on the final analysis of a randomized trial that looked at the effect of human-AI teams prescreening for clinical trial eligibility versus human-only or AI-only prescreening. So give us more good news about AI. What did the study find? Dr. Sweetenham: Yeah, this is a really, a really interesting study. And of course, any of us who have ever been involved in clinical trials will know that accrual is always a problem. And I think most centers have attempted, and some quite successfully managed to develop prescreening programs so that patients are screened by a health care provider or health care worker prior to being seen in the clinic, and the clinical investigator will then already know whether they're going to be eligible for a trial or not. But as you've already said, it's a slow process. It's typically somewhat inefficient and requires a lot of time on the part of the health care workers to actually do this in a successful way. And so, this was a study from Emory University where they took three models of ways in which they could assess the accuracy of the prescreening of charts for patients who are going to be considered for clinical trials. One of these was essentially the regular way of having two research coordinators physically abstract the charts. The second one was an AI platform which would extract longitudinal EHR data. And then the third one was a combination of the two. So the AI would be augmented by the research coordinator or the other way around. As a gold standard, they had three independent oncology reviewers who went through all of these charts to provide what they regarded as being the benchmark for accuracy. In a way, it's not a surprise to me because I think that a number of other systems which have used this combination of human verification of AI-based tools, it actually ultimately concluded that the combination of the two in terms of chart accuracy was for the most part better than either one individually, either the research coordinator or the AI alone. So I'll give you just a few examples of where specifically that mattered. The human plus AI platform was more accurate in terms of tumor staging, in terms of identifying biomarker testing and biomarker results, as well as biomarker interpretation, and was also superior in terms of listing medications. There are one or two other areas where either the AI alone was somewhat more accurate, but the significant differences were very much in favor of a combination of human + AI screening of these patient charts. So, in full disclosure, this didn't save time, but what the authors reported was that there were definite efficiency gains, and presumably this would actually become even more improved once the research coordinators were somewhat more comfortable and at home with the AI tool. So, I thought it was an interesting way of trying to enhance clinical trial accrual up front by this combination of humans and technology, and I think it's going to be interesting to see if this gets adopted at other centers in the future. Dr. Hamilton: Yeah, I think it's really fascinating, all the different places that we can be using AI, and I love the takeaway that AI and humans together are better than either individually. Dr. Sweetenham: Absolutely.  Thanks once again, Dr. Hamilton, for sharing your insights with us today and for all of the incredible work you did to build a robust program. And also, congratulations on what was, I think, a really remarkable ASCO this year, one of the most exciting for some time, I think. So thank you again for that. Dr. Hamilton: Thanks so much. It was really a pleasure to work on ASCO 2025 this year. Dr. Sweetenham: And thank you to our listeners for joining us today. You'll find links to all the abstracts we discussed today in the transcript of this episode. Be sure to catch up on all of our coverage from the Annual Meeting. You can catch up on my daily reports that were published each day of the Annual Meeting, featuring the key science and innovations presented. And we'll have wrap-up episodes publishing in June, covering the full spectrum of malignancies from ASCO25. If you value the insights you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose    Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Right after CineGear, the next big event is already underway. Nino joins in directly from New York to share insights from the BILD Expo, a growing industry trade show hosted by B&H. Now in its second year, the event is quickly gaining recognition across the filmmaking community. But that's not all—this episode is packed with topics! We dive into the impressive results of the Canon EOS R1 lab test, and revisit a discussion we've touched on in previous episodes: why companies like Disney haven't taken legal action against AI platforms like MidJourney, despite clear concerns around copyright and the use of proprietary material in AI training data. So stop reading and hit play—whether you're watching the video or listening to the audio, enjoy this week's episode!   Sponsor: This episode is sponsored by FUJIFILM. Check it out at 21:29 Chapters & Articles Mentioned in This Episode: (00:00) – Introduction   (02:38) - Upcoming Talk at BILD Expo 2025: Let AI Handle the Hustle While You Craft the Story https://www.cined.com/upcoming-talk-at-bild-expo-2025-let-ai-handle-the-hustle-while-you-craft-the-story/   (11:54) - The Efficient Filmmaker MZed Course Series – Part 1: Easy Transcripts and Subtitles https://www.cined.com/the-efficient-filmmaker-series-starting-with-simple-tools-for-transcripts-and-subtitles/   (22:26) - Manfrotto ONE Innovative Hybrid Tripod – First Look https://www.cined.com/manfrotto-one-innovative-hybrid-tripod-first-look/ (31:18) - Canon EOS R1 Lab Test – Rolling Shutter, Dynamic Range and Exposure Latitude https://www.cined.com/canon-eos-r1-lab-test-rolling-shutter-dynamic-range-and-exposure-latitude/   (35:12) - SIGMA 17-40mm f/1.8 DC Art Lens for APS-C Cameras Announced https://www.cined.com/sigma-17-40mm-f-1-8-dc-art-lens-for-aps-c-cameras-announced/   (40:26) - Blackmagic Video Assist 3.20 Update – Adds Blackmagic RAW Recording From Panasonic LUMIX S1II and S1IIE https://www.cined.com/blackmagic-video-assist-3-20-update-adds-blackmagic-raw-recording-from-panasonic-lumix-s1ii-and-s1iie/   (43:04) - Poll: 32-bit Float Audio – A Key Buying Factor for You? https://www.cined.com/poll-32-bit-float-audio-a-key-buying-factor-for-you/   (46:13) - “A Bottomless Pit of Plagiarism” – Disney and NBCUniversal Sue Midjourney AI https://www.cined.com/a-bottomless-pit-of-plagiarism-disney-and-nbcuniversal-sue-midjourney-ai/ (55:16) - DJI Power 1000 & DJI Power Expansion 2000 Review – Is it Worth the Money? https://www.cined.com/dji-power-1000-dji-power-expansion-2000-review-is-it-worth-the-money/ We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

Benedek mesél a fotói nyomtatásáról, az új Polaroid 365 projektjéről, aztán kicsit átmegyünk lifestyle témákra, beszélgetünk sportról, és papír alapú jegyzetelésről. Az adás linkje:⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/150Támogass minket Patreonon:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://tripodcast.hu/patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Csatlakozz a Tripodcast Community Facebook csoporthoz!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://tripodcast.hu/community⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adást a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Fujifilm⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ és a ⁠⁠⁠⁠⁠⁠⁠⁠Manfrotto⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ támogatta!Kövess minket Instán:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/tripodcast_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Az adásban elhangzott témák, linkek:- 5 órás Rolex podcast:https://open.spotify.com/episode/1rhATlBcVbt299Vjy3WniR?si=0392bc6786d04b6c- Bartis Attila - Az eltűnt idő nyoma:https://www.lira.hu/hu/konyv/szepirodalom/memoar-eletrajz-interju/az-eltunt-ido-nyoma

"In each place I have travelled, I have used my camera as an extension of my memory." -- Teju Cole "In photography and in life, always look for the light, if you don't see it, bring it."  John Waire   In this episode, Antonio records from Brooklyn for the last time before his big move to Nebraska. It's a reflective and unscripted conversation, touching on the chaos of packing, the emotional weight of leaving, and a perfectly timed rainbow that showed up outside his window. He and Ward talk about the kind of weather that begs to be photographed and how certain visual moments trigger memories of past images—like Ernst Haas' dramatic skies. Antonio also shares how instant photography is playing a bigger role in his life lately, especially with the Polaroid and Instax cameras he's bringing on the road trip west. Ward recounts how he unexpectedly became the unofficial wedding photographer at a recent event, armed only with a Fuji XS20 and a 23mm lens. What was supposed to be a casual favor turned into a full-on assignment, and he reflects on how his street photography instincts kicked in to help him adapt. They also talk about the overlap between documentary and wedding photography, the influence of photographers like Kevin Mullins and Mel DiGiacomo, and how shooting in a “real life” environment brings out surprising results. There's also a bit of Fujifilm gear talk, some thoughts on photo printing with Polaroid's phone-based printer, and the occasional side trip into DIY diffuser hacks using deli containers.    Subscribe to our Substack Newsletter Help out the show by buying us a coffee! Support the show by purchasing Antonio's Zines. Send us a voice message, comment or question.   Show Links:   Antonio M. Rosario's Website, Vero, Instagram, Bluesky, and Facebook page Ward Rosin's Website, Vero, Bluesky, Instagram and Facebook page. Ornis Photo Website  The Unusual Collective Street Shots Facebook Page Street Shots Instagram     Subscribe to us on: Apple Podcasts Google Podcasts Spotify Amazon Music iHeart Radio

Episode 469 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - 20% OFF Nanlite PavoTube II XR and kits at NanliteUS.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: The X-E5 and XF23mm f/2.8 R WR. (#) Laowa's 8-15mm fisheye wide-zoom. (#) Nikon's latest Z8 firmware adds useful features. (#) ON1 turns 20. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

This week, we're joined by Matt Workman—filmmaker, developer, and creator of Cine Tracer—for a candid look at the shifting landscape of cinematography. We explore how filmmakers can better communicate, justify resources, and protect their creative choices in a rapidly evolving industry, and why futureproofing your skillset now means knowing both a light meter and a game engine. From the emergence of virtual production to the democratization of 3D previsualization, Workman unpacks how technology like Unreal Engine, once reserved for high-budget productions, is becoming a daily tool for working DPs.Matt Workman's Instagram | YouTubePeter Pascucci's Instagram | WebsiteLauren Guiteras's Instagram | WebsiteThis episode is sponsored by Fujifilm, Sandisk and TCP Insurance.

Want to take your photography and your business to the next level? It's not always about buying the latest gear - sometimes, it's the little-known tricks and techniques that make the biggest difference. In this episode, we're revealing some photography secrets that can instantly improve your work and how you run your business.  Whether you're a seasoned photographer or just starting out, there's something in this episode that will change the way you shoot. Tune in and start capturing your best work yet! Episode Promos This episode contains promos for: Elementor Wordpress Website Builder - https://nerdyphotographer.com/recommends/elementor Aftershoot AI Culling - https://aftershoot.com/explore/?ref=nerdyphoto10 Siteground Website Hosting - https://www.siteground.com/go/nerdy Support The Nerdy Photographer Want to help The Nerdy Photographer Podcast? Here are a few simple (and mostly free) ways you can do that: Subscribe to the podcast! Tell your friends about the podcast Sign up for the newsletter - https://nerdyphotographer.com/newsletter Buy a print from the print shop - https://caseyfatchettphotography.pic-time.com/art Follow on Instagram - https://instagram.com/thenerdyphoto Follow on Threads - https://threads.net/@thenerdyphoto Follow in Tiktok - https://tiktok.com/@thenerdyphoto Subscribe to our YouTube Channel - https://www.youtube.com/@CaseyFatchett Get some Nerdy Photographer merchandise - https://www.teepublic.com/stores/nerdy-photographer If you're feeling extra generous, check out our support page - https://nerdyphotographer.com/support-nerdy-photographer/ About My Guest Fred Agho is a Houston-based commercial and portrait photographer who started his journey capturing his collegiate football teammates. His passion for photography has grown into a talent for creating striking portraits that feel authentic and deeply connected. Drawing from his own life experiences, Fred brings a unique perspective to his work, capturing people in a way that feels natural and true to who they are. His ability to connect with his subjects and tell their stories visually has made him a sought-after name in the industry. With an impressive client list that includes FUJIFILM, Publix, SNKR App, Amazon, and Premium Goods, Fred has built a reputation for delivering high-quality, impactful imagery. Each project sharpens his skills and expands his creative vision, resulting in a portfolio filled with compelling and memorable images. You can see Fred's work at his website - https://www.fujifred.com or on Instagram https://instagram.com/@FREDAGHO About The Podcast The Nerdy Photographer Podcast is written and produced by Casey Fatchett. Casey is a professional photographer in the New York City / Northern New Jersey with more than 20 years of experience. He just wants to help people and make them laugh. You can view Casey's wedding work at https://fatchett.com or his non-wedding work at https://caseyfatchettphotography.com    If you have any questions or comments about this episode or any other episodes, OR if you would like to ask a photography related question or have ideas for a topic for a future episode, please reach out to us at https://nerdyphotographer.com/contact  

In this Cine Gear 2025 wrap-up episode of CineD Focus Check, Johnnie is joined by acclaimed cinematographer Markus Förderer, ASC (Red Notice, I Origins, Stowaway) for a rich and thoughtful conversation. Set against the cinematic backdrop of the Universal Studios lot, the two dive deep into the current state of lens technology, digital cinematography, and the importance of preserving the emotional core of storytelling amidst rapid technological change, and the state of the filmmaking industry in general. This Cine Gear 2025 wrap-up episode is sponsored by FUJIFILM. Check out this week's educational One-Minute Tip from them at (08:40)! Markus joined us once before over a year ago in a prior episode of the Focus Check podcast, talking about his project CineFlares after it launched, and his work on Constellation. Check it out here if you missed that episode. From discussing metadata integration in modern lenses and the rise of affordable anamorphic glass, to reflecting on the potential and limitations of AI-generated visuals, this episode offers a grounded and inspiring perspective from one of Hollywood's most thoughtful DPs. Markus also shares insights on his lens test platform CineFlares, custom LUT workflows, and how he chooses optics based on narrative needs, not specs. If you're passionate about the intersection of story, gear, and artistry — this one's for you. Chapters & Show Notes: (00:00) - Intro and Cine Gear impressions Johnnie and Markus open the episode from Cine Gear LA 2025 at Universal Studios and share first impressions of the show. (01:04) - Markus Förderer on his career and latest work From Germany to Hollywood — Markus talks about September 5 (available on Apple TV), Red Notice, and Independence Day: Resurgence. (02:08) - CineFlares: Lens testing reimagined Markus introduces CineFlares.com, a motion-control-based lens test platform with over 100 lens sets and 1,500+ clips. (03:56) - What impressed Markus at Cine Gear He discusses new smart lens tech, metadata tracking, and RED/Nikon's collaboration with Preston. (04:40) - Lens metadata and autofocus on large productions Why autofocus still can't replace a good focus puller — and how hybrid systems are evolving. (07:40) - Small AF rigs for solo shoots Markus shares a jungle shoot story using PDMovie's compact autofocus motor system. https://www.cined.com/pdmovie-live-air-2s-worlds-smallest-wireless-follow-focus-handwheel/ (09:40) - Favorite new lenses at Cine Gear Iron Glass, Zero Optik chip mounts for metadata, and the new Xelmus Apollo “Aura” lenses. (11:28) - Sigma's AIZU full-frame High-Speed Prime line A look at Sigma's new AIZU 1.3 T-stop cine primes and their unique three-dimensional character. https://www.cined.com/sigma-aizu-cinema-prime-lenses-a-talk-with-kazuto-yamaki-san/ (14:10) - What makes a lens cinematic? Markus discusses personality, bokeh, barrel distortion, and why clean ≠ compelling. (18:24) - Flare behavior and subconscious texture How internal lens reflections subtly shape the emotional feel of an image. (19:22) - Affordable anamorphics: SIRUI IronStar A hands-on look at SIRUI's 1.5x squeeze lens series, priced around $1,200. https://www.cined.com/sirui-ironstar-1-5x-t1-9-anamorphic-full-frame-cine-lens-announced/ (23:00) - Cameras that stood out Markus reacts to FUJIFILM's upcoming GFX ETERNA cinema camera and its internal film emulation science. https://www.cined.com/fujifilm-gfx-eterna-2025-release-confirmed-new-technical-details-explained/ (25:09) - FX2, rolling shutter, and global shutter tech The pros and cons of older sensors, rolling shutter artifacts, and RED Komodo X's global shutter advantage. (30:00) - Industry mood check: post-strike recovery Markus sees improving energy in the industry, with more global shoots and cautious optimism. (31:58) - Long takes and storytelling rhythm Thoughts on Apple's The Studio, one-take shots, and why editing still matters emotionally. (34:30) - AI image generation and its limitations Markus argues that real, human-captured moments can't be replaced by AI dream-logic imagery. (37:02) - Final thoughts and sign-off A warm Cine Gear 2025 wrap-up with hopes to reconnect at the same show next year — and a reminder to leave your comments below. Thanks for watching/listening — if you enjoyed this conversation, don't forget to like and subscribe on YouTube and your favorite podcasting platform, and let us know in the comments which topic resonated most with you. See you next time on CineD Focus Check!

With a PetaPixel Membership, not only can you support original PetaPixel reporting and in-depth reviews, but you can also remove ads from the website and gain access to some seriously great perks, too. Members get $15 off the Moment Store, 25% off the PetaPixel Merch Store, and now can download full-resolution RAW files and JPEGs from the latest cameras and lenses. It costs just $3 per month or $30 per year. Join today.Running a camera store is hard enough as it is, but add the complexity of the 2025 economic environment, and The Camera Store's founder Peter Jeune has his work cut out for him. This week on the PetaPixel Podcast, he joins the team to give an update on navigating the fluctuating pricing and product popularity so far in 2025.Check out PetaPixel Merch: store.petapixel.com/ We use Riverside to record The PetaPixel Podcast in our online recording studio.We hope you enjoy the podcast and we look forward to hearing what you think. If you like what you hear, please support us by subscribing, liking, commenting, and reviewing! Every week, the trio go over comments on YouTube and here on PetaPixel, but if you'd like to send a message for them to hear, you can do so through SpeakPipe.In This Episode:00:00 - Intro12:49 - Firstly, no the Kyu review wasn't sponsored content15:13 - Fujifilm moved manufacturing for four X series camera to Japan just for the US market18:41 - We got a ton of new info about the GFX Eterna23:20 - iPadOS is finally getting the update Chris desperately wants27:55 - The SmallRig x Potato Jet tripod is now available in a more compact version31:36 - 31:36 - 7Artisans Cine Primes promise pro quality for $80038:25 - Omnar Lenses made the 5cm f/2 MC FLB lens42:04 - The Camera Store's Peter Jeune talks 2025 pricing and camera popularity1:19:31 - What have you been up to?1:26:16 - Tech support1:36:41 - Feel good story of the week

Once again I Dream of Cameras spans the globe, with Jeff in Prague and Gabe in Los Angeles, and not even a nine-hour time difference can slow us down! In fact, one might say we are utterly devoid of camera viscosity, or “camerosity” for short. In this supersized episode…Jeff unknowingly chatted up Danny Clinch about his Leica Q2 at the Trombone Shorty Soho Session, and the acclaimed photographer was faintly dismissivefor the next two months Jeff's in Prague, where the camera shops (FotoŠkoda, Jan Pazdera) are far too alluringhe's been eyeing a lovely Zeiss Tenax II, a flawed Olympus 35SPn, and a beautifully brassed black Canonflex RMbefore departure, Jeff did the unthinkable: snagged a bargain-basement half-frame Alpa 10s on the ‘Bay - it's half a Swiss cookie and the realization of a lifelong dream!talking Leicas with Dave Tada, Gabe realized he needs a 35mm lens for his Leica III - he already has the 50mm Serenar, so any suggestions?Gabe went to the Fujifilm event for their bizarre new half-a-cookie digital - what did he learn about the elusive x100vi?Gabe has gone half-cookie INSANE with his Olympus Pen FT, so now our friend Sissi Lu has enticed him to give the Pentax One Seven one more try - what will he grab next, the chunky plastic Pentax or the mighty meterless Olympus Pen FV?he's got a portrait shoot coming up, and plans to use the Kiev 60, the Leica III and the Mamiya RZ67as for replenishing his collection, he's up to 27 of a planned 30 cameras Jeff was shooting around Prague when Sudden Fujifilm Battery Death struck again! Fuji's battery displays in both the XPan and GA645 are pure fictionGabe's also been rebuilding his book collection with Duane Michals Portraits and volumes by Sarah Moon and Clifford Coffinlet us now praise John Wade's Retro Cameras, which is what Ralph Bellamy's book should have beenonce again we make it halfway down the depths of our Prodigious Mailbag™Gabe unleashes a raft of thank-yousand adds a final postscript: nature is healing and he's back in the bag business, welcoming a new Nomatic Luma McKinnon

In this episode, we were fortunate to be connected through Blackmagic Design with Victor from TARGO, a Paris-based production company that has been pushing the boundaries of immersive storytelling from the very beginning. Their latest project, “D-Day: The Camera Soldier”, is a groundbreaking documentary created specifically for the Apple Vision Pro. It blends historical footage with interactive and immersive elements, offering a completely new way to experience this pivotal moment in history. Nino and Victor discuss the unique technical challenges involved in producing content for the Vision Pro, and explore why the effort is worthwhile despite the complexities. They also share their vision for how immersive production could become more accessible in the near future, especially with tools like the upcoming Blackmagic URSA Cine Immersive — which we also reported about. In case you own an Apple Vision Pro you can find the Documentary here: https://apps.apple.com/at/app/d-day-the-camera-soldier/id6737838494?l=en-GB Here you can find more infos about TARGO and their Projects: https://www.targostories.com/dday-the-camera-soldier Sponsor: This episode is sponsored by FUJIFILM. Check it out at 26:08 Chapters & Articles Mentioned in This Episode: (00:00) – Introduction: Exploring Immersive Storytelling (01:29) – Background on TARGO and Their Vision (05:37) – Conceptualizing “D-Day: The Camera Soldier” (08:36) – Technical Challenges in Immersive Filmmaking (14:38) – Utilizing Apple Vision Pro Capabilities (18:55) – Integrating Historical Footage and Interactive Elements (21:27) – Post-Production Workflow and Tools (27:40) – Audience Reception and Feedback (31:52 ) – Future of Immersive Documentaries (39:04) – Closing Thoughts and Takeaways   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com 

TurdOrTreasure is ThisWeekInGeek's dedicated review show covering everything from games to movies to tv to electronics and everything between.This Episode:What's New?Fujifilm Printlife Personalized NHL: https://fujifilmprintlife.ca/collections/nhlGames First Impressions Reviews -Warhammer 40,000: Speed Freeks - https://store.steampowered.com/app/2078450/Warhammer_40000_Speed_Freeks/Home - https://store.steampowered.com/app/2575940/Home/Starlight Legacy - https://www.xbox.com/en-us/games/store/starlight-legacy/9P37KTW0D2TNEnGenius ECW516L Wifi 7 AP (Networking Tech Review) - https://www.engeniustech.com/engenius-products/cloud-managed-2x3x3-lite-indoor-tri-band-wifi-7-access-point/The Outlaw Josie Wales (Warner 4K Review) - https://www.blu-ray.com/movies/The-Outlaw-Josey-Wales-4K-Blu-ray/382392/Pale Rider (Warner 4K Review) - https://www.blu-ray.com/movies/Pale-Rider-4K-Blu-ray/382393/Pipistrello And The Cursed Yoyo (PM Studios Inc PC Steam Review) - https://store.steampowered.com/app/2870350/Pipistrello_and_the_Cursed_Yoyo/Your Geekmaster:Alex "The Producer" - https://bsky.app/profile/dethphasetwig.bsky.socialFeedback for the show?:Email: feedback@thisweekingeek.netTwitter: https://twitter.com/thisweekingeekBluesky: https://bsky.app/profile/thisweekingeek.bsky.socialYouTube: https://www.youtube.com/channel/UCc1BfUrFWqEYha8IYiluMyAiTunes: https://podcasts.apple.com/us/podcast/this-week-in-geek/id215643675Spotify: spotify:show:0BHP4gkzubuCsJBhU3oNWXCastbox: https://castbox.fm/channel/id2162049Website: https://www.thisweekingeek.netJune 3, 2025

Dalton Johnson (@storiesbydalton) is a photographer, adventurer, and journalist who has collaborated with renowned brands such as Patagonia, Big Agnes, and Rivian.In this episode, Dalton shares his own experiences in an effort to help photographers understand how they can leverage free work as a tool for growth, the importance of persistence in marketing their craft, and the cyclical process of building a thriving creative career. He breaks down actionable strategies for repeatedly turning passion projects into paid opportunities and shares insights into crafting effective pitches, balancing art with personal fulfillment, and creating work that connects deeply with both clients and audiences.Expect to Learn:Why free work is a powerful tool to build a portfolio and create ROIThe never ending cyclical process of having an idea, creating a body of work, and marketing itWhy engaging with multiple companies daily, will lead to meaningful client relationshipsPractical methods to market creative projectsHelpful tips on creating effective pitchesDalton's links:Youtube: https://www.youtube.com/@storiesbydaltonWebsite: https://dalton-johnson.com/LinkedIn: https://www.linkedin.com/in/daltonjohnsonmedia/Sponsor:Thanks to Tamron for being our lead sponsor this episode! Explore the 18-300mm all-in-one zoom lens for Fujifilm and Sony APS-C Mirrorless cameras and soon for Nikon Z and Canon RF mounted cameras. Right now, enjoy $100 off on this lens! You can visit www.tamron-americas.com or your local Tamron authorized dealer. Our Links:Join our subreddit where you can share stories and ask questions:https://www.reddit.com/r/photographermindset/Subscribe to TPM's Youtube page and watch full length episodes: https://www.youtube.com/thephotographermindset/Make a donation via PayPal for any amount you feel is equal to the value you receive from our podcast episodes! Donations help with the fees related to hosting the show:https://paypal.me/podcasttpm?country.x=CA&locale.x=en_USThanks for listening!Go get shooting, go get editing, and stay focused.@sethmacey@mantis_photography@thephotographermindsetSupport the show

Fuji hat mit der X Half ein neues Kamera-Modell auf den Markt gebracht, das in Sachen Analog-Simulation den nächsten Schritt geht. Inspiriert davon bringt Michael mit einem schwarzen Kaffee in der Hand Ideen mit, wie im Prinzip jede Digitalkamera mit einem analogen Feeling versehen werden kann. Und stellt sich (und Euch!) die Frage: Warum das ganze überhaupt? Wir freuen uns auf Eure Kommentare, hier unter dem Post oder in der Freundeskreis-Community!

Episode 468 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Calibrite's Spring savings at Calibrite.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Fujifilm's new X half. (#) Nikon takes the top spot for the first time. (#) Sebastião Salgado passes away. (#) X Summit in Shanghai. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Finally, the long-anticipated new Sony FX2 cinema camera has arrived at the CineD headquarters for a full stress test — and that's exactly what we did. Johnnie has already spent some time with the camera, produced a short documentary, and shares insights on what worked for him and what didn't. Additionally, we cover new updates on the latest version of Google's AI video generator, Neo, along with the usual gear updates for the week. Join us to discover all the details in this "Sony FX2 podcast". Sponsor: This episode is sponsored by FUJIFILM. Check it out at 29:04 Chapters & Articles Mentioned in This Episode: (00:00) -  Intro (03:26) - Sony FX2 Review – An Entry-Level, Full-Frame, Cinema Line Camera. Is the Price Right? https://www.cined.com/sony-fx2-review-an-entry-level-full-frame-cinema-line-camera-is-the-price-right/   (30:05) - Google DeepMind Veo 3 and Flow Unveiled for AI “Filmmaking” https://www.cined.com/google-deepmind-unveils-veo-3-and-flow-for-ai-filmmaking/   (39.26) - AI Flood on Adobe Stock: Nearly Half of All Images Now AI-Generated https://www.cined.com/ai-flood-on-adobe-stock-nearly-half-of-all-images-now-ai-generated/    (42:45) - Darren Aronofsky Partners with Google DeepMind on Generative AI Short Film Initiative https://www.cined.com/darren-aronofsky-partners-with-google-deepmind-on-generative-ai-short-film-initiative/   (48:11) - B&H BILD Expo Returns to New York City in June, with CineD Talk – Free Registration Now Open https://www.cined.com/bh-bild-expo-returns-to-new-york-city-in-june-with-cined-talk-free-registration-now-open/   (50:06) - Poll: What is the Most Innovative Camera Brand? https://www.cined.com/poll-innovation-in-cameras-which-is-your-favorite-brand/   (53:19) - RØDE Wireless Micro Bluetooth iOS Update Adds Direct Pairing with iPhones https://www.cined.com/rode-wireless-micro-bluetooth-ios-update-adds-direct-pairing-with-iphones/   (55:43) - Hollyland LARK MAX 2 Officially Launched – 32-bit Float, On-board TC & Four-TX Support https://www.cined.com/hollyland-lark-max-2-officially-launched-32-bit-float-on-board-tc-four-tx-support/ (1:00:35) - Mandy Walker Makes History as ASC's First Female President https://www.cined.com/mandy-walker-makes-history-as-ascs-first-female-president/   (01:02:48) - Pro Tip: Sensor Crop Feature in CineD Lens Coverage Tool https://www.cined.com/pro-tip-sensor-crop-feature-in-lens-coverage-tool/   We hope you enjoyed this episode! You have feedback, comments, or suggestions? Write us at podcast@cined.com   

Neale is trying to cheer Kev up, who is sitting in a blacked out room in beautiful Malmesbury, counting down the hours, minutes and seconds until he can escape the UK for the sunnier climes of España! On the show, the boys discuss using Pictime as an art gallery, software solutions for back-up, the foto app, fixing up a retiring camera, the best compact camera in the Fujifilm range to travel with, switching to video using an X-T4, and we also feature the Zine work of Adam Ramjean, as he photographs the Notting Hill Carnival. Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

Rachel Clark, BSC, brings a poetic realism to the screen, and in this special edition episode recorded at the Camerimage Festival, she reveals how she constructs that visual language. Joining hosts Ava Benjamin Shorr and Lauren Guiteras to reflect on the making of “Edge of Summer”, a lyrical coming-of-age film set in the haunting landscapes of Cornwall. Clark unpacks her immersive handheld approach, the challenge of lighting with only headlamps, and the deeply collaborative relationship with director Lucy Cohen. Their discussion explores the aesthetics of memory, adolescence, and the subtle power of image-making that trusts the viewer's emotional literacy.If you are enjoying the podcast, please consider supporting our efforts on Patreon.Rachel Clark's Instagram | WebsiteAva Benjamin Shorr's Instagram | WebsiteLauren Guiteras's Instagram | WebsiteThis episode is sponsored by Fujifilm, Creamsource and Sandisk, with special thanks to Kondor Blue.

Dr. John Sweetenham and Dr. Erika Hamilton discuss top abstracts that will be presented at the 2025 ASCO Annual Meeting, including research on tech innovations that could shape the future of oncology. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'm delighted to be joined today by Dr. Erika Hamilton, a medical oncologist and director of breast cancer and gynecologic cancer research at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Hamilton is also the chair of the 2025 ASCO Annual Meeting Scientific Program, and she's here to tell us about some of the key abstracts, hot topics, and novel approaches in cancer care that will be featured at this year's Annual Meeting. Our full disclosures are available in the transcript of this episode. Dr. Hamilton, it's great to have you on the podcast today, and thanks so much for being here. Dr. Erika Hamilton: Thanks, Dr. Sweetenham. I'm glad to be here. Dr. John Sweetenham: Dr. Hamilton, the Presidential Theme of the Annual Meeting this year is ‘Driving Knowledge to Action: Building a Better Future,' and that's reflected in many of the sessions that will focus on action-oriented guidance to improve care for our patients. And as always, there'll be great presentations on practice-changing abstracts that will change treatment paradigms and transform care. Can you tell us about some of the hot topics this year and what you're particularly excited about? Dr. Erika Hamilton: You're right. Dr. Robin Zon's theme is ‘Driving Knowledge to Action: Building a Better Future,' and you're going to see that theme really interlaced throughout the ASCO program this year. We had a record number of submissions. Over 5,000 abstracts will be published, and there'll be about 3,000 presentations, either in oral format or poster presentations. We have 200 dynamic sessions. Many of the discussants will be highlighting key takeaways and how we can translate action-oriented guidance to better treat our patients to build a better future. Our state-of-the-art science will include a Plenary Session. This will feature presentations as well as discussion of each of the presentations for clinical late-breaking abstracts. We have Clinical Science Symposia that I'm particularly excited about this year. These will feature key abstracts as well as discussions and a foundational talk around the subject. We're covering novel antibody-drug conjugate targets, turning “cold” tumors “hot” to include CAR T, as well as the future of cancer detection. There'll be rapid oral abstracts, case-based panels, and this will also feature interactive audience polling and case discussions. I also want to highlight the community connection opportunities. There will be 13 Communities of Practice that will be meeting on-site during ASCO, and there's also really a plethora of networking opportunities for trainees and early-career professionals, a Women's Networking Center, a patient advocate space, and I'm happy to report there will also be live music out on the terrace this year at ASCO. Dr. John Sweetenham: Well, that's going to be a really great addition. I have to say, I think this is always a special time of year because excitement starts to mount as the meeting gets closer and closer. And once the abstracts are out there, I certainly personally feel that the excitement builds. Talking of abstracts, let's dive into some of the key abstracts for this year's meeting. I'd like to start out by asking you about Abstract 505. This reports on 15-year outcomes for women with premenopausal hormone receptor-positive early breast cancer in the SOFT and TEXT trials. It assesses the benefits of adjuvant exemestane and ovarian function suppression or tamoxifen and ovarian function suppression. So, could you talk us through this and tell us what you think the key takeaways from this abstract are? Dr. Erika Hamilton: Absolutely. This is essentially the SOFT and TEXT trials. They are trials that we've been following for quite some time, evidenced by the 15-year outcome. And I think it really answers two very important questions for us regarding adjuvant endocrine therapy for patients that are facing hormone receptor-positive disease. The benefit of ovarian function suppression for one, and then second, the benefit of exemestane over tamoxifen, which is our SERM [selective estrogen receptor modulator]. So, in terms of the SOFT trial, when we talk about distance recurrence-free interval, which I really think is probably the most meaningful because secondary cancers, et cetera, are not really what we're getting at here. But in terms of distant recurrence-free interval, certainly with tamoxifen, using tamoxifen plus ovarian function suppression adds a little bit. But where we really get additional benefits are by moving to exemestane, an aromatase inhibitor with the ovarian function suppression. So, for example, in SOFT, for distant recurrence-free interval for patients that have received prior chemotherapy, the distance recurrence-free interval was 73.5% with tamoxifen, bumped up just a tiny bit to 73.8% with ovarian function suppression. But when we used both ovarian function suppression and switched to that aromatase inhibitor, we're now talking about 77.6%. It may seem like these are small numbers, but when we talk about an absolute benefit of 4%, these are the type of decisions that we decide whether to offer chemotherapy based on. So, really just optimizing endocrine therapy really can provide additional benefits for these patients. Just briefly, when we turn to TEXT, similarly, when we look at distance recurrence-free interval for our patients that are at highest risk and receive chemotherapy, tamoxifen and ovarian function suppression, 79%; 81% with exemestane and ovarian function suppression. And when we talk about our patients that did not receive chemotherapy, it increased from 91.6% up to 94.6%—very similar that 3% to 4% number. So, I think that this is just very important information when counseling our patients about the decisions that they're going to make for themselves in the adjuvant setting and how much we want to optimize endocrine therapy. Dr. John Sweetenham: Thanks so much for your insight into that. Dr. Erika Hamilton: Yeah, absolutely. So, let's turn to hematologic malignancies. Abstract 6506 reports exciting results on the new agent ziftomenib in relapsed/refractory NPM1-mutant acute myeloid leukemia. This is a phase 1b clinical activity study and safety results. This was the pivotal KOMET-001 study. And my question is, will this new agent fulfill an unmet need in this NPM1 space? Dr. John Sweetenham: Yeah, great question. And I think the answer is almost certainly ‘yes'. So, just as some brief background, NPM1 mutation is known to be a driver of leukemogenesis in around 30% of patients with AML, and it's a poor prognostic factor. And typically, about 50% of these patients will relapse within a year of their first-line therapy, and only around 10% of them will get a subsequent complete remission with salvage therapy. Menin inhibitors, which disrupt the interaction between menin and KMT2A, are known to be active in NPM1-mutated as well as in KMT2A-rearranged AML. And ziftomenib is a selective oral menin inhibitor, which in this study was evaluated at a dose of 600 mg once a day, as you mentioned, a phase 1b/2 study, which is multicenter and presented by Dr. Eunice Wang from Roswell Park. It's a relatively large study of 112 patients who were treated with this standard dose with relatively short median follow-up at this time. The median age was 69 years, and median prior therapies were two, but with a range of one to seven. And I think very importantly, 60% of these patients had previously been treated with venetoclax, and 23% of them had had a prior transplant. Looking at the results overall for this study, the overall response rate was 35%, which is actually quite impressive. Specifically for those patients in the phase 2 part of the study, around 23% achieved a CR [complete remission] or CRh [complete remission with partial hematologic recovery]. What's very interesting in my mind is that the response rates were comparable in venetoclax-naive and venetoclax-exposed patients. And the drug was very well tolerated, with only 3% of patients having to discontinue because of treatment-related adverse events. And I think the authors appropriately conclude that, first of all, the phase 2 primary endpoint in the study was met, and that ziftomenib achieved deep and durable responses in relapsed and refractory NPM1-mutated AML, regardless of prior venetoclax, with good tolerance of the drug. And so, I think putting all of this together, undoubtedly, these data do support the potential use of this agent as monotherapy and as a new option for those patients who have relapsed or refractory NPM1-mutated acute myeloid leukemia. So, let's move on a little bit more now and change the subject and change gears completely and talk about circulating tumor DNA [ctDNA]. This has been a hot topic over a number of years now, and at this year's meeting, there are quite a few impactful studies on the use of ctDNA. We have time to focus on just one of these, and I wanted to get your thoughts on Abstract 4503. This is from the NIAGARA trial, which looks at ctDNA in patients with muscle-invasive bladder cancer who receive perioperative durvalumab. Could you tell us a little bit about this study? Dr. Erika Hamilton: So, this was the phase 3 NIAGARA trial, and this is literally looking for patients with muscle-invasive bladder cancer that are cisplatin-eligible, and the addition of durvalumab to neoadjuvant chemotherapy. So here, this is a planned exploratory analysis of ctDNA and the association with clinical outcomes from NIAGARA. So, this is really the type of study that helps us determine which of our patients are more likely to have a good outcome and which of our patients are more likely not to. There were 1,000 randomized patients in this study, and 462 comprised the biomarker-evaluable population. There were about half in the control arm and half in the durvalumab arm. And overall, the ctDNA-positive rate at baseline was about 57%, or a little over half, and that had decreased to about 22% after neoadjuvant treatment. ctDNA clearance rates from baseline to pre-radical cystectomy was about 41% among those with durvalumab and 31% among those in control. And the non-pCR rate was 97% among patients with pre-cystectomy ctDNA-positive status. So, this really gives us some information about predicting who is going to have better outcomes here. We did see a disease-free survival benefit with perioperative durvalumab, and this was observed in post-cystectomy ctDNA-positive as well as the ctDNA-negative groups. Shifting gears now to GI cancer, Abstract 3506 is a long-term safety and efficacy study of sotorasib plus panitumumab and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer. And this is the CodeBreaK-101 study. What are your thoughts on this study? Dr. John Sweetenham: Yeah, thanks. A very interesting study, and this abstract builds upon the phase 3 CodeBreaK-300 trial, which I think has just been published in the Journal of Clinical Oncology. This showed that the combination of sotorasib and panitumumab improved clinical outcomes in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer. The current abstract, as you mentioned, reports the CodeBreaK-101 trial. And this was a phase 1b trial where FOLFIRI therapy was added to sotorasib and panitumumab in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer. The abstract reports the overall and progression-free survival results, as well as some updated safety and response data. So, in this study, patients with this particular mutation who had received at least one prior systemic treatment but were KRAS G12C inhibitor-naive were enrolled into an expansion cohort of the CodeBreaK-101 protocol. And these patients received what apparently now recommended as the standard phase 2 dose of sotorasib of 960 mg daily, plus panitumumab and a standard dose of FOLFIRI. And the primary endpoint of the study was safety, and secondary endpoints included confirmed response, overall response, and progression-free survival, as assessed by the investigator. And by November of last year, 40 patients had been enrolled into this study. Common treatment-related adverse events were cutaneous; some patients developed neutropenia, and stomatitis was fairly widespread. Discontinuation of sotorasib because of adverse events was only seen in 1% of patients, although patients did have to discontinue because of toxicity from some of the other agents in the combination. Looking at the results of this study, the updated objective response rate was 57.5%, and the disease control rate was estimated at 92%, going on 93%, with a median time to response of 1.6 months and a median response duration of 6 months. After a median follow-up of 29.2 months, the median progression-free survival was 8.2 months, and the overall survival 17.9 months. So, the authors have concluded that this combination, including sotorasib, panitumumab, and FOLFIRI, does appear to show quite promising long-term efficacy in pretreated patients with this specific mutation. The ongoing phase 3 study they mentioned, CodeBreaK-301, is aiming to evaluate this combination against the standard of care in the first-line setting for patients with KRAS G12C-mutated colorectal cancer. So, promising results, and we'd be very interested to see how this particular combination performs in the frontline. Dr. Erika Hamilton: Fantastic. Thanks so much for sharing that. Let's shift gears again and really talk about digital technology. I feel that we're all going to have to get much better with this, and really, there are a lot of promises for our patients coming here. There are a lot of abstracts at ASCO that are focusing on innovations in digital technology, including a really interesting psychosocial digital application for caregivers of patients that are undergoing hematopoietic stem cell transplantation. Can you tell us a little bit about this? It's Abstract 11000. Dr. John Sweetenham: Yeah, absolutely. This abstract certainly caught my eye, and I think it's intriguing for a number of reasons, partly because it's app-based, and partly also because it specifically addresses caregiver burden and caregiver needs in the oncology setting, which I think is especially important. And although the context, the clinical context of this study, is hematopoietic stem cell transplantation, I think it has potential applications way beyond that. We all know that caregivers of patients undergoing stem cell transplantation have significant quality-of-life struggles. They are well-documented to have significant psychological and emotional strain before, during, and after stem cell transplantation. And this abstract describes an application called BMT-CARE, which is aimed at improving caregivers' quality of life, caregiver burden, mood symptoms, and coping skills, and so on. So, this was a single-center, randomized trial from MGH [Massachusetts General Hospital] of this app for stem cell transplant caregivers, compared with usual care in those individuals. And the eligible patients, or eligible individuals, were adults caring for patients with heme malignancy undergoing either an autologous or an allogeneic stem cell transplant. Patients were randomly assigned either to use the app or for usual care. And the app itself—and I think it'll be interesting to actually see this at the meeting and visualize it and see how user-friendly and so on it is—but it comprises five modules, which integrate psychoeducation, behavior change, stress management, and they're delivered through a kind of interactive platform of educational games and videos. And then participants were self-reporting at baseline and then 60 days after transplant. So, around 125 patients were enrolled in this study, of around 174 who were initially approached. So, just over 70% uptake from caregivers, which is, I think, relatively high, and evenly distributed between the two randomized arms. And the majority of the participants were spouses. And at 60 days post-stem cell transplant, the intervention participants reported a better quality of life compared with those who received usual care. If you break this down a little bit more, these participants reported lower caregiving burden, lower incidence of depression, fewer PTSD symptoms, and overall better coping skills. So, the authors conclude that this particular app, a digital health intervention, led to pretty substantial improvements in quality of life for these caregivers. So, intriguing. As I said, it'll be particularly interesting to see how this thing looks during the meeting. But if these kind of results can be reproduced, I think this sort of application has potential uses way beyond the stem cell transplant setting. Dr. Erika Hamilton: Yeah, I find that just so fascinating and very needed. I think that the caregiving role is often underestimated in how important that is for the patient and the whole family, and really giving our caregivers more tools in their toolbox certainly is quite helpful. Dr. John Sweetenham: Absolutely. Well, the meeting is getting closer, and as I mentioned earlier, I think anticipation is mounting. And I wanted to say thanks so much to you for chatting with me today about some of the interesting advances in oncology that we're going to see at this year's meeting. There is a great deal more to come. Our listeners can access links to the studies we've discussed today in the transcript of this episode. I'm also looking forward, Dr. Hamilton, to having you back on the podcast after the Annual Meeting to dive into some of the late-breaking abstracts and some of the other key science that's captured the headlines this year. So, thanks once again for joining me today. Dr. Erika Hamilton: Thanks so much for having me. Pleasure. Dr. John Sweetenham: And thank you to our listeners for joining us today. Be sure to catch my “Top Takeaways from ASCO25.” These are short episodes that will drop each day of the meeting at 5:30 p.m. Eastern Time. So, subscribe to the ASCO Daily News Podcast wherever you prefer to listen, and join me for concise analyses of the meeting's key abstracts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   More on today's speakers: Dr. John Sweetenham   Dr. Erika Hamilton @erikahamilton9   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:     Dr. John Sweetenham:     No relationships to disclose  Dr. Erika Hamilton: Consulting or Advisory Role (Inst): Pfizer, Genentech/Roche, Lilly, Daiichi Sankyo, Mersana, AstraZeneca, Novartis, Ellipses Pharma, Olema Pharmaceuticals, Stemline Therapeutics, Tubulis, Verascity Science, Theratechnologies, Accutar Biotechnology, Entos, Fosun Pharma, Gilead Sciences, Jazz Pharmaceuticals, Medical Pharma Services, Hosun Pharma, Zentalis Pharmaceuticals, Jefferies, Tempus Labs, Arvinas, Circle Pharma, Janssen, Johnson and Johnson   Research Funding (Inst): AstraZeneca, Hutchison MediPharma, OncoMed, MedImmune, Stem CentRx, Genentech/Roche, Curis, Verastem, Zymeworks, Syndax, Lycera, Rgenix, Novartis, Millenium, TapImmune, Inc., Lilly, Pfizer, Lilly, Pfizer, Tesaro, Boehringer Ingelheim, H3 Biomedicine, Radius Health, Acerta Pharma, Macrogenics, Abbvie, Immunomedics, Fujifilm, eFFECTOR Therapeutics, Merus, Nucana, Regeneron, Leap Therapeutics, Taiho Pharmaceuticals, EMD Serono, Daiichi Sankyo, ArQule, Syros Pharmaceuticals, Clovis Oncology, CytomX Therapeutics, InventisBio, Deciphera, Sermonix Pharmaceuticals, Zenith Epigentics, Arvinas, Harpoon, Black Diamond, Orinove, Molecular Templates, Seattle Genetics, Compugen, GI Therapeutics, Karyopharm Therapeutics, Dana-Farber Cancer Hospital, Shattuck Labs, PharmaMar, Olema Pharmaceuticals, Immunogen, Plexxikon, Amgen, Akesobio Australia, ADC Therapeutics, AtlasMedx, Aravive, Ellipses Pharma, Incyte, MabSpace Biosciences, ORIC Pharmaceuticals, Pieris Pharmaceuticals, Pieris Pharmaceuticals, Pionyr, Repetoire Immune Medicines, Treadwell Therapeutics, Accutar Biotech, Artios, Bliss Biopharmaceutical, Cascadian Therapeutics, Dantari, Duality Biologics, Elucida Oncology, Infinity Pharmaceuticals, Relay Therapeutics, Tolmar, Torque, BeiGene, Context Therapeutics, K-Group Beta, Kind Pharmaceuticals, Loxo Oncology, Oncothyreon, Orum Therapeutics, Prelude Therapeutics, Profound Bio, Cullinan Oncology, Bristol-Myers Squib, Eisai, Fochon Pharmaceuticals, Gilead Sciences, Inspirna, Myriad Genetics, Silverback Therapeutics, Stemline Therapeutics

Episode 467 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Calibrite's Spring savings at Calibrite.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Zenfolio promises to do better. (#) (#) Tamron's plan through 2026. (#) CaptureOne rebrands and adds some features. (#) TTArtisan's 35mm f/1.4. (#) Nikon discontinues the D6. (#) Nik Collection 8 is out. (#) ACDSee's Photoshop alternative. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Neale invites Kev to street photograph and adventure with him in Kolkata and Varanasi as he prepares for the next 2026 Photowalk adventure in India, but will he say yes. Also on the show a VERY special offer from our wonderful sponsor Pictime, called 72, plus an invite to come and join us on a special Pictime Zoom show on Wednesday 14th May at 6pm UK time, invite URL below. Questions into the show about lost custom settings, website picture layout nightmares, finding a discreet camera system for shooting unobtrusively, the classic Fujinon lens line-up for the X-system, protecting gear from bangs and knocks in the bag, ChatGPT accuses Neale of stealing Kev's 35mm, a 500mm beast, and battery talk.  THE BIG ZOOM INVITE for 14th March 6pm UK time: https://www.fujicast.co.uk/pictime  Email the show with your questions: click@fujicast.co.uk  Pic Time: https://www.pic-time.com/ - use FUJICAST when creating an account for discount offers to apply For links go to the showpage.

Episode 466 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Benro Spring savings at BenroUSA.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: This photographer shows what not to do. (#) Canon's new 75-300mm f/4-5.6 sure seems familiar. (#) Nikon looks to hit 50 in short order. (#) MAP Camera's top 20 is telling. (#) Grecco goes to the mat for photographers. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Episode 465 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Benro Spring savings at BenroUSA.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Sony's FE 50-150mm f/2 G Master. (#) Tamron's 18-300mm f/3.5-6.3 for APS-C. (#) The newest additions to Photoshop and Lightroom. (#) Profoto's new Spot Small. (#) The Viltrox AF 35mm f/1.2 LAB. (#) Flickr makes a key change to its service. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).

Episode 464 of the Lens Shark Photography Podcast In This Episode If you subscribe to the Lens Shark Photography Podcast, please take a moment to rate and review us to help make it easier for others to discover the show. Sponsors: - Build Your Legacy with Fujifilm. Latest savings at FujfilmCameraSavings.com - Shop with the legends at RobertsCamera.com, and unload your gear with UsedPhotoPro.com - Great deals on Calibrite gear at Calibrite.com. - More mostly 20% OFF codes at LensShark.com/deals. Stories: Nikon's new Z5 II. (#) This Canon lens can't keep it together. (#) A legend has passed. (#) ProGrade Digital's latest offerings. (#) Key updates for Nikon's Zf. (#) Panasonic finally gets onboard. (#)   Connect With Us Thank you for listening to the Lens Shark Photography Podcast! Connect with me, Sharky James on Twitter, Instagram Vero, and Facebook (all @LensShark).